GEMCOVAC VACCINES

Gennova has developed an mRNA-based vaccine against COVID-19, GEMCOVAC®-19, which overcomes the limitations associated with the currently approved mRNA vaccines.

The currently approved mRNA vaccines have certain inherent limitations, like:

• Ultra-low temperature logistics
• Ease of Manufacturing
• Supply of raw materials
• Scalability
• Technology transfer

GEMCOVAC®-19 is stable at 2–8 °C and can be considered superior in terms of deployability in India and other developing nations (especially LMICs) compared to other approved mRNA vaccines. 

In GEMCOVAC®-19, the mRNA is adsorbed on the surface of the nano-lipid emulsion (as opposed to it being

entrapped in other mRNA vaccines using NLPs), thereby easing manufacturability and minimizing losses.

This also makes the process scalable and amenable to technology transfer – a must for the democratization of mRNA-based technology globally to eliminate inequitable vaccine distribution globally.

In addition to the obvious application to infectious diseases, mRNA-based vaccines have the potential for multiple administrations in patients with low intrinsic immunity, thereby opening up bright prospects for developing novel therapeutics. Creating such an unprecedented ‘disease agnostic mRNA-based technology platform’ empowers the world to be ready for future pandemics.